Premium
Paranasal Sinus Malignancies: An 18‐Year Single Institution Experience
Author(s) -
Myers Larry L.,
Nussenbaum Brian,
Bradford Carol R.,
Teknos Theodoros N.,
Esclamado Ramon M.,
Wolf Gregory T.
Publication year - 2002
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1097/00005537-200211000-00010
Subject(s) - medicine , malignancy , sinus (botany) , stage (stratigraphy) , surgery , multivariate analysis , adenoid cystic carcinoma , retrospective cohort study , ethmoid sinus , paranasal sinuses , carcinoma , paleontology , botany , biology , genus
Objectives To characterize a single institution experience with management of paranasal sinus malignancies during an 18‐year time period, report long‐term survival rates, and identify prognostic factors. Study Design Retrospective chart review. Methods Studied were 141 patients treated for a paranasal sinus malignancy at a single institution from 1980 to 1997 with a minimum 3‐year follow‐up. Gender, age, TNM stage, anatomic site, pathology, treatment, and recurrence rates were reviewed. Multivariate analysis was performed to determine factors affecting survival. Results The male to female ratio was 1.6:1, and the median patient age was 60 years. Most patients presented with T3/T4 or locally advanced disease (88%), N0 status (96%), and M0 status (96%). The maxillary sinus was the most commonly affected site (70%), followed by the ethmoid sinus (26%). The most common malignancy was squamous cell carcinoma (51%), followed by adenoid cystic carcinoma (12%) and adenocarcinoma (11%). Sixty‐two percent of this study group underwent surgery as part of a multimodality curative treatment plan or alone as curative treatment. Eighteen patients (13%) had unresectable local disease and received non‐surgical palliative treatment. Kaplan‐Meier analysis revealed the 5‐year and 10‐year disease‐specific survival was 52% and 35%, respectively. Multivariate analysis revealed T4 stage ( P = .005), N‐positive stage ( P = .009), and M‐positive stage ( P = .018) negatively impacted survival. Seventy‐two patients (51%) developed recurrent disease at a median time of 336 days after initial treatment. Conclusions Most patients with paranasal sinus malignancies presented with locally advanced disease. Advanced T stage, regional, and distant metastasis are highly predictive of poor survival. Recurrence rate is high and typically occurs within the first year after treatment.